# US 2021/0277030 A1 · Amide compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277030 A1
- Document ID: US20210277030A1
- Status: Published application
- Kind: A1
- Application number: 17/316,185
- Filed: 2021-05-10
- Published: 2021-09-09
- Earliest claimed: 2013-07-03
- Assignees: Takeda Pharmaceutical Company Limited
- Applicants: Takeda Pharmaceutical Company Limited
- Inventors: Satoshi Yamamoto; Junya Shirai; Mitsunori Kono; Yoshihide Tomata; Ayumu Sato; Atsuko Ochida; Yoshiyuki Fukase; Shoji Fukumoto; Tsuneo Oda; Hidekazu Tokuhara; Naoki Ishii; Yusuke Sasaki
- Web page: https://patentgrep.com/patent/US20210277030A1

## CPC

- C07F 7/0812: {comprising a heterocyclic ring}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 237/22: having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated (peptides C07K)
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 207/12: Oxygen or sulfur atoms
- C07D 207/26: 2-Pyrrolidones
- C07D 209/18: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/62: attached in position 4
- C07D 213/64: attached in position 2 or 6
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 233/72: Two oxygen atoms, e.g. hydantoin
- C07D 237/14: Oxygen atoms
- C07D 239/36: as doubly bound oxygen atom or as unsubstituted hydroxy radical
- C07D 239/54: as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 261/12: Oxygen atoms
- C07D 271/10: 1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D 295/14: substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 309/06: Radicals substituted by oxygen atoms
- C07D 309/08: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 487/04: Ortho-condensed systems
- C07F 7/081: {comprising at least one atom selected from the elements N, O, halogen, S, Se or Te}
- C07F 7/10: containing nitrogen {having a Si-N linkage}
- C07F 7/30: Germanium compounds
- C07K 5/06078: {and aromatic or cycloaliphatic}
- C07K 5/0812: {and aromatic or cycloaliphatic}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.

## Claims

### Claim at position 1

-16. (canceled)

### Claim 17

A method for the treatment of inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis or systemic lupus erythematosus (SLE), which comprises administering an effective amount of a compound represented by the following formula (I):
wherein
Ring A is a benzene ring optionally further substituted by 1 to 3 substituents selected from
(1) a halogen atom, and
(2) a cyano group;
R1 is
(1) a group represented by the formula: -Q(R1a)(R1b)(R1c)
wherein
Q is a carbon atom or a silicon atom, and
R1a, R1b and R1c are each independently a C1-6 alkyl group, or
(2) a neopentyl group;
R2 is
(1) a group represented by the formula:
wherein
R5 is
(A) a C1-6 alkyl group optionally substituted by 1 to 3 C1-6 alkoxy groups, or
(B) a C1-6 alkoxy group,
(2) a bicyclic fused heterocyclic group selected from dihydrobenzofuryl and indazolyl, each optionally substituted by 1 to 3 C1-6 alkyl groups, or
(3) a group represented by the formula -L-Z1:
wherein
L is a bond; and
Z1 is
(A) a C3-10 cycloalkyl group optionally substituted by 1 to 3 halogen atoms, or
(B) tetrahydropyranyl;
R3 is
(1) a hydrogen atom, or
(2) a C1-6 alkyl group; and
R4 is
(1) a C1-6 alkyl group optionally substituted by 1 to 7 substituents selected from
(a) a 3- to 8-membered monocyclic non-aromatic heterocyclic group selected from dihydropyrimidinyl, dihydropyridyl, dihydropyridazinyl, imidazolidinyl, tetrahydropyranyl, morpholinyl, piperidyl and tetrahydropyrimidinyl, each optionally substituted by 1 to 3 substituents selected from
(i) an oxo group, and
(ii) a C1-6 alkyl group,
(b) a 5- or 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from
(i) a C1-6 alkyl group, and
(ii) a hydroxy group,
(c) a 8- to 14-membered fused bicyclic aromatic heterocyclic group selected from indazolyl and benzimidazolyl,
(d) a halogen atom,
(e) a hydroxy group,
(f) a cyano group,
(g) a carboxy group,
(h) a C1-6 alkylsulfonyl group, and
(i) an amino group optionally mono- or di-substituted by C1-6 alkyl-carbonyl group(s),
(2) a 3- to 8-membered monocyclic non-aromatic heterocyclic group selected from pyrrolidinyl, oxazolidinyl, azetidinyl, piperidyl and tetrahydropyranyl, each optionally substituted by 1 to 3 substituents selected from
(a) an oxo group,
(b) a hydroxy group,
(c) a halogen atom, and
(d) a C1-6 alkyl-carbonyl group,
(3) a 5-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 hydroxy groups,
(4) a C3-10 cycloalkyl group optionally substituted by 1 to 3 halogen atoms, or
(5) an amino group optionally mono- or di-substituted by C1-6 alkyl group(s), provided that
α-(acetylamino)-N-[4-(1,1-dimethylethyl)phenyl]-cyclopentaneacetamide
is excluded,
or a salt thereof, to a mammal.

### Claim 18 (depends on 17)

The method of claim 17, wherein the substituent that Ring A optionally further has is a fluorine atom or a chlorine atom.

### Claim 19 (depends on 17)

The method of claim 17, wherein R1 is a tert-butyl group, a neopentyl group or a trimethylsilyl group.

### Claim 20 (depends on 17)

The method of claim 17, wherein R2 is
(1) a group represented by the formula:
wherein R5 is an alkoxy group or an alkoxyalkyl group,
(2) a tetrahydro-2H-pyran-4-yl group,
(3) a 4,4-difluorocyclohexyl group,
(4) a 1-methyl-1H-indazol-5-yl group, or
(5) a 2,3-dihydro-1-benzofuran-5-yl group.

### Claim 21 (depends on 17)

The method of claim 17, wherein R3 is a hydrogen atom or a methyl group.

### Claim 22 (depends on 17)

The method of claim 17, wherein the compound is (3S)—N-((1R)-2-((4-tert-Butyl-3-fluorophenyl)amino)-1-(4,4-difluorocyclohexyl)-2-oxoethyl)-5-oxopyrrolidine-3-carboxamide or a salt thereof.

### Claim 23 (depends on 17)

The method of claim 17, wherein the compound is N-((1R)-2-((3,5-Difluoro-4-(trimethylsilyl)phenyl)amino)-1-(4-methoxyphenyl)-2-oxoethyl)-3-hydroxy-N-methyl-1,2-oxazole-5-carboxamide or a salt thereof.

### Claim 24 (depends on 17)

The method of claim 17, wherein the compound is (2R)—N-(4-tert-Butyl-3,5-difluorophenyl)-2-(((3-hydroxy-1,2-oxazol-5-yl)acetyl)amino)-2-(1-methyl-1H-indazol-5-yl)acetamide or a salt thereof.

### Claim 25 (depends on 17)

The method of claim 17, wherein the compound is (3R)—N-((1R)-2-((3-fluoro-4-(trimethylsilyl)phenyl)amino)-1-(4-(methoxymethyl)phenyl)-2-oxoethyl)-5-oxopyrrolidine-3-carboxamide or a salt thereof.

### Claim 26 (depends on 17)

The method of claim 17, wherein the compound is selected from the group consisting of
(3S)—N-((1R)-2-((3-fluoro-4-(trimethylsilyl)phenyl)amino)-1-(4-(methoxymethyl)phenyl)-2-oxoethyl)-5-oxopyrrolidine-3-carboxamide,
N-((1R)-2-((3-fluoro-4-(trimethylsilyl)phenyl)amino)-1-(4-methoxyphenyl)-2-oxoethyl)-3-hydroxy-N-methyl-1,2-oxazole-5-carboxamide,
N-(2-((3-fluoro-4-(trimethylsilyl)phenyl)amino)-1-(4-(methoxymethyl)phenyl)-2-oxoethyl)-5-oxopyrrolidine-3-carboxamide,
(2R)-2-(((2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetyl)amino)-N-(3-fluoro-4-(trimethylsilyl)phenyl)-2-(4-(methoxymethyl)phenyl)acetamide,
(2R)—N-(3-fluoro-4-(trimethylsilyl)phenyl)-2-(4-(methoxymethyl)phenyl)-2-(((4-oxopyridazin-1(4H)-yl)acetyl)amino)acetamide,
1-acetyl-N-((1R)-2-((3-fluoro-4-(trimethylsilyl)phenyl)amino)-1-(4-(methoxymethyl)phenyl)-2-oxoethyl)piperidine-4-carboxamide,
(2R)—N-(3-fluoro-4-(trimethylsilyl)phenyl)-2-(((3-hydroxy-1,2-oxazol-5-yl)acetyl)amino)-2-(4-(methoxymethyl)phenyl)acetamide,
(2R)—N-(3-fluoro-4-(trimethylsilyl)phenyl)-2-(4-(methoxymethyl)phenyl)-2-(((4-oxopyridin-1(4H)-yl)acetyl)amino)acetamide,
(2R)—N-(4-tert-butyl-3-fluorophenyl)-2-(4-(methoxymethyl)phenyl)-2-(((6-oxopyrimidin-1(6H)-yl)acetyl)amino)acetamide,
(3R)—N-((1R)-2-((4-tert-butyl-3-fluorophenyl)amino)-1-(4-(methoxymethyl)phenyl)-2-oxoethyl)-5-oxopyrrolidine-3-carboxamide,
N-((1R)-2-((3,5-difluoro-4-(trimethylsilyl)phenyl)amino)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl)-3-hydroxy-N-methyl-1,2-oxazole-5-carboxamide,
N-((1R)-2-((4-tert-butyl-3-chlorophenyl)amino)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl)-3,3,3-trifluoro-2-hydroxypropanamide,
(2R)—N-(2,5-difluoro-4-(trimethylsilyl)phenyl)-2-(4-(methoxymethyl)phenyl)-2-(((5-methyl-1,3,4-oxadiazol-2-yl)acetyl)amino)acetamide, and
(2R)—N-(4-tert-butyl-3-fluorophenyl)-2-(((2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetyl)amino)-2-(4-(methoxymethyl)phenyl)acetamide,
or a salt thereof.

### Claim 27 (depends on 17)

The method of claim 17, wherein the compound is (3R)—N-((1R)-2-((4-tert-butyl-3-fluorophenyl)amino)-1-(4-(methoxymethyl)phenyl)-2-oxoethyl)-5-oxopyrrolidine-3-carboxamide.
